Chang Gung Memorial Hospital
Taoyuan, 333, Taiwan
NCT Number: NCT01948154
Cerebral palsy (CP) encompass a group of non-progressive, non-contagious motor conditions that cause physical disability in human development. It is not infrequently to note concurrent impairment in sensory, intelligence, vision and auditory in those patients. Many studies have documented Cerebral palsy is associated with a variety of neuromotor disorders that frequently affect the speech production system. The speech function impairment varied widely due to different severity of diseases involved. The investigators hypothesize such impairment of speech function may affect degree of social participation and eventually the quality of life (QoL).
Looking for future studies?
Notify Me2 year–12 year
All sexes
Observational
Taoyuan, 333, Taiwan
Cerebral palsy (CP) encompass a group of non-progressive, non-contagious motor conditions that cause physical disability in human development. It is not infrequently to note concurrent impairment in sensory, intelligence, vision and auditory in those patients. Many studies have documented Cerebral palsy is associated with a variety of neuromotor disorders that frequently affect the speech production system. The speech function impairment varied widely due to different severity of diseases involved. The investigators hypothesize such impairment of speech function may affect degree of social participation and eventually the quality of life (QoL).
The investigators study aim in this project include: (1) to find the differences in speech function in normal developed children and in children with CP with different severity; (2) the relationship between speech function and QoL in children with CP; (3) to seek the predictable factor involving motor speech function in children with CP from the framework of International Classification of Functioning, Disability and Health - Children and Youth Version (ICF-CY).
This will be a 3-year longitudinal project recruiting 110-130 children in total. The investigators will have children with CP (n=60~80) and normal (n=50) from 2-12 years old under consent of their family. The investigator's study will be based on structure of ICF-CY. In the first year, basic clinical assessments including motor, mental, vocabulary, motor speech function, general development, and subjective questionnaires on adaptation, participation, development and quality of life will be collected. During the second to the third year, all measurements will be repeated in the end of 6- and 12-month to follow the performance of children with CP and those with normal development.
The anticipated outcomes of this study are: (1) to observe the longitudinal change of speech function and QoL in children with CP. (2) Using ICF-CY items in rehabilitation services to describe the speech function and participation of social life for children with CP. (3)To identify the influencing factors and predictors of motor speech function for children with CP.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Inclusion criteria
Exclusion criteria
Time frame: baseline, 6 month, 12 month
change of CDIIT
Time frame: baseline, 6 month, 12 month
change of Mental Ability (BSID-II, WPPSI-R, WISC-IV)in 6 month, 12 month follow up
Time frame: baseline, 6 month,12 month
Motor Speech Assessment (VMPAC, PCC)in 6 month, 12 month follow up
Time frame: baseline, 6 month, 12 month
Language Assessment (PPVT-R; CLST)in 6 month, 12 month follow up
Chang Gung Memorial Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05194319
Behavior, Brain Damage, Chronic
Gaziantep, Sahinbey, Turkey (Türkiye)
View Trial DetailsNCT05206461
Brain Damage, Chronic, Brain Diseases
Konya, Karatay, Turkey (Türkiye)
View Trial DetailsNCT04259814
Behavior, Brain Damage, Chronic
Chicago, Illinois, United States
View Trial DetailsNCT03277027
Behavior, Brain Damage, Chronic
Suwon, South Korea
View Trial Details